@article{KannBlessmannWinkelmannetal.2021,
  author    = {Kann, Simone and Blessmann, Joerg and Winkelmann, Yvonne and Hansen, Jessica and Maya Amaya, Leonardo J. and Rivera Salcedo, Gadith E. and Halas, Hussein El and Schmidt-Chanasit, Jonas and Keoviengkhone, Latdamone and Sopraseuth, Vatsana and Deschermeier, Christina and Mika, Angela},
  title     = {Dengue virus detection in Lao PDR and Colombia: Comparative evaluation of PCR tests},
  series = {Tropical Medicine \& International Health},
  volume    = {26},
  journal   = {Tropical Medicine \& International Health},
  number    = {10},
  doi       = {10.1111/tmi.13670},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-262703},
  pages     = {1296 -- 1302},
  year      = {2021},
  abstract  = {Objectives Dengue virus (DENV) detection by polymerase chain reaction (PCR) facilitates diagnosis of dengue fever, which is the most frequent arboviral disease globally. Two studies were performed in countries with high dengue incidence, to assess the diagnostic performance of different PCR techniques. Methods/Results Two hundred and seventy-nine acute phase blood samples from febrile patients were analyzed for DENV by the RealStar Dengue RT-PCR kit (Altona Diagnostics) as gold standard in comparison with the Tropical Fever Core multiplex PCR (Fast Track Diagnostics). In total, 102 samples collected in Savannakhet Province (Lao PDR, Southeast Asia) in 2013 and 35 samples from Valledupar (Colombia, South America) tested positive for DENV by RealStar RT-PCR. In comparison, the Tropical Fever Core multiplex PCR detected 65.0\% (65/102) and 68.6\% (24/35) of these samples as positive for DENV in Savannakhet and Valledupar, respectively. Diagnostic sensitivity of the multiplex PCR strongly correlated with viral load. A subset of DENV PCR-confirmed samples was additionally tested by BNITM in house Dengue Type RT-PCR in comparison with two commercial test kits (RealStar Dengue Type RT-PCR [Altona Diagnostics], Dengue differentiation PCR [Fast Track Diagnostics]). The leading dengue serotype in Savannakhet was DENV-3 (58\% [29/50]), while DENV-1 (53.8\% [14/26]) was the predominant serotype found in samples collected in Valledupar by BNITM-type PCR. However, three DENV serotypes were circulating in Valledupar and in Savannakhet. In 2015, additional studies found predominantly DENV-4 (71\% [12/17]) in Savannakhet. Conclusions Both studies emphasized that routine diagnostics in both regions will benefit from an expanded use of highly sensitive pan-dengue PCRs.},
  language  = {en}
}
@article{ColvillBoothNilletal.2016,
  author    = {Colvill, Emma and Booth, Jeremy and Nill, Simeon and Fast, Martin and Bedford, James and Oelfke, Uwe and Nakamura, Mitsuhiro and Poulsen, Per and Worm, Esben and Hansen, Rune and Ravkilde, Thomas and Rydh{\"o}g, Jonas Scherman and Pommer, Tobias and af Rosenschold, Per Munck and Lang, Stephanie and Guckenberger, Matthias and Groh, Christian and Herrmann, Christian and Verellen, Dirk and Poels, Kenneth and Wang, Lei and Hadsell, Michael and Sothmann, Thilo and Blanck, Oliver and Keall, Paul},
  title     = {A dosimetric comparison of real-time adaptive and non-adaptive radiotherapy: a multi-institutional study encompassing robotic, gimbaled, multileaf collimator and couch tracking},
  series = {Radiotherapy and Oncology},
  volume    = {119},
  journal   = {Radiotherapy and Oncology},
  number    = {1},
  doi       = {10.1016/j.radonc.2016.03.006},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-189605},
  pages     = {159-165},
  year      = {2016},
  abstract  = {Purpose: A study of real-time adaptive radiotherapy systems was performed to test the hypothesis that, across delivery systems and institutions, the dosimetric accuracy is improved with adaptive treatments over non-adaptive radiotherapy in the presence of patient-measured tumor motion. Methods and materials: Ten institutions with robotic(2), gimbaled(2), MLC(4) or couch tracking(2) used common materials including CT and structure sets, motion traces and planning protocols to create a lung and a prostate plan. For each motion trace, the plan was delivered twice to a moving dosimeter; with and without real-time adaptation. Each measurement was compared to a static measurement and the percentage of failed points for gamma-tests recorded. Results: For all lung traces all measurement sets show improved dose accuracy with a mean 2\%/2 mm gamma-fail rate of 1.6\% with adaptation and 15.2\% without adaptation (p < 0.001). For all prostate the mean 2\%/2 mm gamma-fail rate was 1.4\% with adaptation and 17.3\% without adaptation (p < 0.001). The difference between the four systems was small with an average 2\%/2 mm gamma-fail rate of <3\% for all systems with adaptation for lung and prostate. Conclusions: The investigated systems all accounted for realistic tumor motion accurately and performed to a similar high standard, with real-time adaptation significantly outperforming non-adaptive delivery methods.},
  language  = {en}
}
@article{GriebschKernHansenetal.2022,
  author    = {Griebsch, Nora-Isabell and Kern, Johanna and Hansen, Jonas and Rullmann, Michael and Luthardt, Julia and Helfmeyer, Stephanie and Dekorsy, Franziska J. and Soeder, Marvin and Hankir, Mohammed K. and Zientek, Franziska and Becker, Georg-Alexander and Patt, Marianne and Meyer, Philipp M. and Dietrich, Arne and Bl{\"u}her, Matthias and Ding, Yu-Shin and Hilbert, Anja and Sabri, Osama and Hesse, Swen},
  title     = {Central serotonin/noradrenaline transporter availability and treatment success in patients with obesity},
  series = {Brain Sciences},
  volume    = {12},
  journal   = {Brain Sciences},
  number    = {11},
  issn      = {2076-3425},
  doi       = {10.3390/brainsci12111437},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-290294},
  year      = {2022},
  abstract  = {Serotonin (5-hydroxytryptamine, 5-HT) as well as noradrenaline (NA) are key modulators of various fundamental brain functions including the control of appetite. While manipulations that alter brain serotoninergic signaling clearly affect body weight, studies implicating 5-HT transporters and NA transporters (5-HTT and NAT, respectively) as a main drug treatment target for human obesity have not been conclusive. The aim of this positron emission tomography (PET) study was to investigate how these central transporters are associated with changes of body weight after 6 months of dietary intervention or Roux-en-Y gastric bypass (RYGB) surgery in order to assess whether 5-HTT as well as NAT availability can predict weight loss and consequently treatment success. The study population consisted of two study cohorts using either the 5-HTT-selective radiotracer [\(^{11}\)C]DASB to measure 5-HTT availability or the NAT-selective radiotracer [\(^{11}\)C]MRB to assess NAT availability. Each group included non-obesity healthy participants, patients with severe obesity (body mass index, BMI, >35 kg/m\(^2\)) following a conservative dietary program (diet) and patients undergoing RYGB surgery within a 6-month follow-up. Overall, changes in BMI were not associated with changes of both 5-HTT and NAT availability, while 5-HTT availability in the dorsal raphe nucleus (DRN) prior to intervention was associated with substantial BMI reduction after RYGB surgery and inversely related with modest BMI reduction after diet. Taken together, the data of our study indicate that 5-HTT and NAT are involved in the pathomechanism of obesity and have the potential to serve as predictors of treatment outcomes.},
  language  = {en}
}